Scarica l'app Stockscreener
26.40
1.11%
0.29
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $390,145.00 in Stock - MarketBeat
Hongbo Lu Buys 25,985 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $109,657.60 in Stock - MarketBeat
Zenas BioPharma Adopts Amended Short-Term Incentive Plan - TipRanks
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 56% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% HigherWhat's Next? - MarketBeat
Will Zenas BioPharma Inc. outperform during market ralliesWeekly Trade Analysis & Low Risk Investment Opportunities - mfd.ru
Can Zenas BioPharma Inc. be the next market leaderTreasury Yields & Community Consensus Stock Picks - mfd.ru
ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Nigeria
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - bdtonline.com
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - Yahoo Finance
Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm
Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq
Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
A Big Boss Bet on Zenas BioPharma’s Future - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys 57,000 Shares - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 8.9%Here's Why - MarketBeat
Chipmakers Recap: What is the target price for Zenas BioPharma Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - GlobeNewswire Inc.
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Published on: 2026-02-01 19:33:40 - baoquankhu1.vn
Investment Report: What are analysts price targets for ArrowMark Financial CorpWeekly Investment Summary & Daily Stock Momentum Reports - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Is Zenas BioPharma Inc.’s growth already priced in2025 Top Gainers & Safe Entry Trade Reports - mfd.ru
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - Chartmill
Zenas BioPharma Slams Investor's Revamped Fraud Claim - Law360
Can Zenas BioPharma Inc be the next market leaderOptions Play & Short-Term High Return Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma (ZBIO) Stock Analysis: Promising 99.75% Upside Potential For Investors - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPhar - The National Law Review
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 6.6%Here's Why - MarketBeat
Zenas Bio rises as Wedbush launches with Outperform on lead asset - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contac - The National Law Review
Zenas BioPharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Zenas crashes as late-stage trial data for lead asset disappoint - MSN
Portfolio Update: Will Zenas BioPharma Inc outperform during market ralliesWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Moving Averages: Can Northann Corp navigate macro headwindsPortfolio Return Summary & Comprehensive Market Scan Reports - baoquankhu1.vn
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1%Time to Sell? - MarketBeat
Zenas BioPharma Stock Pre-Market (-4.4%): Shareholder Lawsuit Investigation Announced - Trefis
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):